Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Familial amyloidotic polyneuropathy (FAP) type I and the therapies].

Rinsho shinkeigaku = Clinical neurology - 1 Dec 1995

Ando Y, Tanaka Y, Yamashita T, Tashima K, Sakashita N, Nakamura M, Uchino M, Ando M

Abstract excerpt

Since autonomic dysfunction in familial amyloidotic polyneuropathy (FAP) Type I is recognized in the early stage of FAP patients and restricts their daily life, we developed various therapies for various autonomic manifestations: Loading glucose was often effective for faintness caused by hypoglycemia and erythropoietin was also good therapy for orthostatic hypotension as well as anemia found in the end stage of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to FAP gene
Share to Amyloid Neuropathies
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lipoproteins, LDL

Share to Liver Transplantation

Share to Mice, Transgenic

Share to Prealbumin

Source

Identifiers

PMID: 8752420

Genes

FAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Familial amyloidotic polyneuropathy (FAP) type I and the therapies].PMID 8752420Read ↗

[Therapeutic strategy for familial amyloid polyneuropathy (FAP)].Semantic proximity Read ↗

[Analyses of amyloid formation mechanism in familial amyloidotic polyneuropathy and therapeutic trial].Semantic proximity Read ↗

[Familial amyloidotic polyneuropathy].Semantic proximity Read ↗

[Familial amyloidotic polyneuropathy].Semantic proximity Read ↗

[Treatment of familial amyloid polyneuropathy].Semantic proximity Read ↗

[Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].Semantic proximity Read ↗

[Clinical pathology and molecular genetics on familial amyloidotic polyneuropathy].Semantic proximity Read ↗

Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and managementSemantic proximity Read ↗

[Pathogenesis and treatment of CIDP].Semantic proximity Read ↗

[What gnaws at the heart and gets on the nerves].Semantic proximity Read ↗

[Familial amyloidotic polyneuropathy (FAP type I) with late-onset; siblings showing heterogeneity in age of onset].Semantic proximity Read ↗

[Recent advances of the treatment in metabolic disorders].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.